（原标题：上海医药现2笔大宗交易 合计成交28.10万股） | 成交量 | 成交金 额 | 成交价 | 相对当日 收盘折溢 | 买方营业 | | | --- | --- | --- | --- | --- | --- | | （万 | | 格 | | | 卖方营业部 | | 股） | （万 | （元） | 价 | 部 | | | | 元） | | （%） | | | | 15.59 12.51 | 281.46 225.75 | 18.05 18.05 | 0.00 0.00 | 机构专用 机构专用 | 瑞银证券有限责任公司上海花园石桥路证券营业 部 瑞银证券有限责任公司上海花园石桥路证券营业 部 | 上海医药12月12日大宗交易平台共发生2笔成交，合计成交量28.10万股，成交金额507.21万元。成交价 格均为18.05元。从参与大宗交易营业部来看，机构专用席位共出现在2笔成交的买方或卖方营业部中， 合计成交金额为507.21万元，净买入507.21万元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报•数据宝统计显示，上海医药今日收盘价为18.05元，上涨1.35%，日换手率为1 ...

Group 1 - *ST Hu Ke received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws, leading to a formal case being opened against the company [2] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management and operations [4] - The main business of *ST Hu Ke involves the trade of agricultural and chemical products, classified under "F51 Wholesale Industry" according to the CSRC [4] Group 2 - As of December 12, *ST Hu Ke's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [5] - Humanwell Healthcare announced that it received an administrative penalty notice from the CSRC for failing to disclose non-operating fund occupation and related transactions in its annual reports, which contained significant omissions and false records [5] - Humanwell Healthcare's stock will be subject to risk warnings starting December 16, with a daily price fluctuation limit of 5% after being placed on the risk warning board [6] Group 3 - Humanwell Healthcare, established in 1993, is a leading pharmaceutical company in Hubei Province, with a strong presence in various therapeutic areas and a comprehensive pharmaceutical value chain [8] - As of December 12, Humanwell Healthcare's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [9]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医药商业板块主力资金净流出3.56亿元，游资资金净流出3613.06万元，散户资 金净流入3.92亿元。医药商业板块个股资金流向见下表： 证券之星消息，12月12日医药商业板块较上一交易日下跌0.97%，海王生物领跌。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。医药商业板块个股涨跌见下表： ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][9]. Core Insights - The company's wholesale business is gradually recovering in Q3, with a projected stable growth outlook for the coming year. The total revenue for the first three quarters of 2025 was 15.758 billion yuan, a decrease of 1.47% year-on-year, while the net profit attributable to shareholders was 646 million yuan, down 9.81% [3][4]. - The decline in revenue and profit is primarily attributed to the impact of centralized procurement policies and hospital drug sales control, which have led to a temporary decrease in sales volume and profit margins in the wholesale segment. However, improvements in product structure and cost reduction efforts are expected to support a gradual recovery in performance [4][5]. - The retail and industrial segments showed steady growth, with retail revenue increasing by 8.17% to 2.591 billion yuan and industrial revenue rising by 6.44% to 860 million yuan in the first three quarters of 2025 [5]. Financial Performance Summary - For Q1-Q3 2025, the gross margin was 10.88%, a decrease of 0.88 percentage points, while the net profit margin was 4.10%, down 0.38 percentage points. The company’s operating cash flow net amount was 135 million yuan, an increase of 10.09% [4]. - The company’s revenue projections for 2025-2027 are 21.133 billion yuan, 22.221 billion yuan, and 23.383 billion yuan, respectively, with net profits expected to be 828 million yuan, 873 million yuan, and 922 million yuan [9][11]. Strategic Initiatives - The company has implemented an employee stock ownership plan and stock option incentive plan to enhance talent retention and core team cohesion. The first transfer of shares under the employee stock ownership plan has been completed, involving 52 employees [6]. - To diversify its product offerings and enhance competitiveness, the company has established a wholly-owned subsidiary and signed an investment agreement with Suninflam Ltd. for the development of an innovative monoclonal antibody drug targeting inflammation-related factors in epilepsy [8].

来源：新浪证券-红岸工作室 12月11日，华人健康跌4.75%，成交额2.93亿元。两融数据显示，当日华人健康获融资买入额2395.67万 元，融资偿还2889.94万元，融资净买入-494.27万元。截至12月11日，华人健康融资融券余额合计1.27 亿元。 融资方面，华人健康当日融资买入2395.67万元。当前融资余额1.27亿元，占流通市值的5.68%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，华人健康12月11日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量100.00股，融券余额1504.00元，超过近一年60%分位水平，处于较高位。 资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药97.60%，其他(补充)2.40%。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康 ...

（文章来源：证券日报） 证券日报网讯 12月11日晚间，瑞康医药发布公告称，公司股票交易价格于2025年12月9日至2025年12月 11日连续三个交易日内收盘价格跌幅偏离值累计超过20%，属于股票交易异常波动。公司未发现近期公 共媒体报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息。 ...

（文章来源：证券日报） 证券日报网讯 12月11日，国药一致在互动平台回答投资者提问时表示，公司于11月29日披露了估值提 升计划，将围绕稳经营、提质效，做强医药分销及零售主业，提高分红比率，加强与投资者交流，持续 提升信息披露质量等方式增进市场认同，努力推动公司价值合理反映上市公司质量。 ...

（编辑 丛可心） 证券日报网讯 12月10日晚间，重药控股发布公告称，控股子公司重药股份以公开挂牌方式转让持有的 化医财务公司20%股权，摘牌方即受让方为重庆建峰工业集团有限公司，转让价格26，477.11万元，化 医财务公司已于2025年12月9日完成工商变更登记，重药股份不再持有化医财务公司股权。 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 20% relative to the benchmark index within the next six months [9][15]. Core Insights - The company reported a revenue of 215.07 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 2.60%. The pharmaceutical industrial segment saw a slight decline in sales revenue by 0.66%, while the pharmaceutical commercial segment grew by 2.91% [3][4]. - The net profit attributable to the parent company for the same period was 5.147 billion yuan, an increase of 26.96%. However, the non-recurring net profit decreased by 26.79% to 2.699 billion yuan [3][4]. - The company’s innovative drug business achieved sales revenue of 40.7 billion yuan, growing over 25% year-on-year, indicating strong growth in this segment [5]. Financial Performance Summary - For Q1-Q3 2025, the company’s gross margin was 10.42%, a decrease of 0.63 percentage points, while the net profit margin increased by 0.46 percentage points to 2.39% [4]. - The company’s R&D investment for the first nine months of 2025 was 1.729 billion yuan, accounting for 9.52% of the pharmaceutical industrial sales revenue [6]. - The forecasted revenues for 2025, 2026, and 2027 are 286.67 billion yuan, 301.44 billion yuan, and 317.14 billion yuan, respectively, with net profits expected to be 5.701 billion yuan, 5.538 billion yuan, and 6.074 billion yuan [9][11].

分红方面，华人健康A股上市后累计派现8000.20万元。 融券方面，华人健康12月10日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量100.00股，融券余额1579.00元，超过近一年60%分位水平，处于较高位。 资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药97.60%，其他(补充)2.40%。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康实现营业收入38.92亿元，同比增长19.06%；归母净利润1.57亿元， 同比增长45.21%。 来源：新浪证券-红岸工作室 12月10日，华人健康涨1.54%，成交额3.73亿元。两融数据显示，当日华人健康获融资买入额2692.86万 元，融资偿还4651.78万元，融资净买入-1958.92万元。截至12月10日，华人健康融资融券余额合计1.32 ...